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RATIONALE: Aspirin exacerbated respiratory disease (AERD) is a
challenging upper and lower respiratory disease which requires joint
management between allergists and otolaryngologists. Complete sinus
surgery followed by aspirin desensitization (AD) appears to improve
outcomes long-term. Recent studies have demonstrated a relationship
between high preoperative, pre-AD sinonasal symptoms scores and
severity of reactions during AD. In this study, we provide the first evidence
for using stratified preoperative, pre-AD sinonasal symptom scores to
predict postoperative, post-AD outcomes.
METHODS: Retrospective chart review of all patients with aspirin
challenge-proven AERD who underwent complete endoscopic sinus
surgery followed by AD. Preoperative, postoperative/pre-AD, and short-
(<2 months) and long-term (>6 months) postoperative/post-AD sinonasal
symptom scores were collected (22-item Sino-Nasal Outcomes Test,
SNOT-22). A longitudinal linear mixed-effects model was used for data
analysis.
RESULTS: Preoperative SNOT-22 scores (n547) were divided into
tertiles (cutoffs of 36 and 54 indicating mild [22.5613.7], moderate
[44.3612.2], and severe [72.9619.7] disease). Postoperative, pre-AD
SNOT-22 in all disease groups decreased and were not significantly
different (12.3613.7, 11.1612.2, and 22.7619.7; p50.074). Following
AD, only the severe group scores worsened (35.0620.3, p<0.001),
whereas the other groups demonstrated negligible change (9.3614.3 and
14.4612.2). At 6 months post-AD, all groups redemonstrated convergence
in symptom scores (23.7620.9, 19.4615.4, and 31.0627.6, p50.304).
CONCLUSIONS: Preoperative SNOT-22 scores may be used as a
predictor of postoperative, post-AD patient-reported outcomes in AERD.
Patients withmild andmoderate diseasemay derive benefit fromAD alone,
while those with severe disease may require additional interventions (e.g.,
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RATIONALE: Atopic dermatitis (AD) is a chronic illness with recurrent
relapses. Allergen-specific immunotherapy (ASIT) directed towards IgE
has proven effective in respiratory allergy. In Mexico however, there is
currently no report of the clinical response in patients with ASIT and AD.
METHODS: Observational, ambispective study including patients 3-16
years of age with atopic dermatitis and respiratory allergy who atended the
outpatent clinic from January 2016 to June 2017. Group 1: patients that
started ASIT 6 months prior to inclusion and observed for 9 months total;Group 2: patients with ASIT started upon study initiation. In both groups
SCORAD, use of medicines, quality of life and flares were evaluated.
RESULTS: A total of 17 patients were included. 9 in group 1 which had 6
patients (66.6%) with mild AD, 3 (33.3%) with moderate and none with
severe AD. Group 2 had a total of 8 patients: 4 patients (50%) with mild
AD, 2 patients (25%) moderate and 2 (25%) with severe AD.
Dermatophagoides farinae and pteronyssinus, Atriplex canescens,
Fraxinus americana, Junglans regia and Canis familiaris were allergens
included in the ASIT. The mean SCORAD was compared in the initial
and last visit finding a statistical significance with p50.002 in group 1,
p50.005 in group 2 and in both groups combined p50.001. Days of treat-
ment required and flares were reduced and improvement fo quality of life
was seen in both groups.
CONCLUSIONS: ASIT is effective in patients with AD, resulting in
significant clinical changes regarding SCORAD, quality of life, need of
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RATIONALE: Rhinovirus (RV) infections are the most common cause of
viral URIs, and in the majority of persons self-resolve. However, in others,
viral URIs can progress to bacterial sinusitis and induce chronic
rhinosinusitis (CRS) exacerbations.
METHODS: We conducted a comprehensive PRISMA review through
April 2018 based onMEDLINE, Embase,Web of Science-SCI and CPCI-S
using keywords: RV, respiratory virus, sinusitis, and airway epithelial cells.
The goal of this systematic review was to (1) determine the prevalence
between RVand CRS, (2) investigate the pathophysiologic mechanisms by
which RVinduces sinonasal inflammation, (3) study the changes that occur
after experimental RV inoculation, and (4) explore the treatment options
available for RV-associated sinusitis. Data regarding study design, research
question, intervention, subjects, outcomes, and biases was extracted.
RESULTS: The initial search yielded 2395 unique abstracts, of which 600
were selected for full-text review, and 147 included in the final review. We
determined that (1) the prevalence of RV infections is increased in those
with CRS, (2) RV-A and RV-C challenges in vitro to sinonasal epithelia
produce robust cytokine responses and differential gene changes, (3) hu-
mans challenged in vivo with RV secrete local and systemic inflammatory
mediators with radiographic mucosal thickening and (4) no current thera-
pies have produced consistent and significant resolution of disease.
CONCLUSIONS: RV infections are common in persons with CRS, and
incite inflammatory reactions that may result in CRS exacerbations and
progression of disease. Further studies assessing RV-species, and the host-
virome response are required to develop new strategies targeting RV-
induced CRS.
